Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 12/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746679 | 0.84 | BRAF (0.71) | BRAFMAPK14 | |
| SCHEMBL29459596 | 0.84 | BRAF (0.71) | BRAFMAPK14 | |
| SCHEMBL4967010 | 0.84 | MAPK14 (0.48) | BRAFMAPK14CSF1RAURKBKDR | |
| SCHEMBL4747084 | 0.83 | BRAF (0.57) | BRAFMAPK14 | |
| SCHEMBL4750071 | 0.81 | BRAF (0.57) | BRAFMAPK14 | |
| SCHEMBL4750107 | 0.77 | BRAF (0.66) | BRAF | |
| SCHEMBL5000815 | 0.75 | BRAF (0.63) | BRAF | |
| SCHEMBL5004339 | 0.74 | BRAF (0.62) | BRAF | |
| SCHEMBL4967069 | 0.74 | BRAF (0.62) | BRAFMAPK14 | |
| SCHEMBL3942284 | 0.74 | BRAF (0.71) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | claimed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | claimed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | BRAF 1/4885MAPK14 104/4885CSF1R 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.